[The future of asthma therapy].
Today bronchial asthma is regarded as a chronic inflammatory disease of the airways, which is modulated and controlled by immunological mechanisms. This new understanding of its pathogenesis is reflected in novel asthma treatment strategies. Newer treatments no longer aim at blocking effects of single mediators or at bronchodilation, but try to intervene in specific immunological mechanisms. An overview of future developments in asthma therapy is presented, with special emphasis on the anti-IgE concept of E-25.
Solèr
M
M
Abteilung für Pneumologie, Universitätsspital Basel.
D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007073:Immunoglobulin E / Q000097:blood; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D018836:Inflammation Mediators; D010726:Phosphodiesterase Inhibitors; D007073:Immunoglobulin E